Data Integrity a Top Concern for Manufacturers, FDA Says
When a pharmaceutical or active pharmaceutical ingredient manufacturer has data integrity issues, that’s likely the tip of the iceberg, Sarah Barkow, of FDA’s Office of Manufacturing Quality, told attendees of the Pharma and Biopharma Outsourcing Association’s annual conference in Rockville, MD.
“You need to worry about [data integrity] from all levels of the supply chain,” she said. “Once there are data integrity lapses, you know there are other things you don’t know.”
In terms of remediation, she said companies need to follow three steps: conduct a comprehensive investigation, perform risk assessments and form a remediation and management strategy that includes a corrective action plan.
Barkow further explained how when a company receives a 90-day classification letter with an official action indicated (OAI), the first of which FDA began sending in December 2017, a warning letter is to be expected. And in terms of warning letters, these are the top three concerns Barkow noted:
Ying Zhang, branch chief of FDA’s Office of Process and Facilities, meanwhile explained a new review approach that integrates the process and facility assessment and is meant to reduce a lot of information requests and comments.
And among the common issues or deficiencies in pre-approval inspections, Zhang pointed to a lack of detailed information regarding operations or tests to be conducted at each facility, a facility that’s not performing a function listed in an application or unaware it’s referenced in an application, or even a facility that is no longer in commercial operation.
“I’ve seen two applications submitted recently where companies said their facility wouldn’t be ready for an inspection yet and they received a refuse to file,” she noted.
We have completed our migration to a new platform and are pleased to introduce the updated site.
What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.
We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.